Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study.
Weight loss ameliorates arterial hypertension and glucose metabolism in obese patients, but the dietary approach is unsatisfactory because obesity relapses. Durable reduction of body weight, obtained through major nonreversible surgical procedures, such as jejunal and gastric bypass, allows improvement of glucose metabolism and arterial blood pressure in morbid (grade 3) obesity. Laparoscopic adjustable gastric banding (LAGB) is a minimally invasive and reversible surgical procedure that yields a significant reduction of gastric volume and hunger sensation. In this study, 143 patients with grade 3 obesity [27 men and 116 women; age, 42.9 +/- 0.83 yr; body mass index (BMI), 44.9 +/- 0.53 kg/m(2); normal glucose tolerance (NGT; n = 77); impaired glucose tolerance (IGT; n = 47); type 2 diabetes mellitus (T2DM; n = 19)] underwent LAGB and a 3-yr follow-up for clinical (BMI, waist circumference, waist to hip ratio, and arterial blood pressure) and metabolic variables (glycosylated hemoglobin, fasting insulin and glucose, insulin and glucose response to oral glucose tolerance test, homeostasis model assessment index, total and high-density lipoprotein cholesterol, triglycerides, uric acid, and transaminases). At baseline and 1 yr after LAGB, patients underwent computerized tomography and ultrasound evaluation of visceral and sc adipose tissue. One-year metabolic results were compared with 120 obese patients (51 men and 69 women; age, 42.9 +/- 1.11 yr; BMI, 43.6 +/- 0.46 kg/m(2); NGT, n = 66; IGT, n = 8; T2DM, n = 46) receiving standard dietary treatment. LAGB induced a significant and persistent weight loss and decrease of blood pressure. Greater metabolic effects were observed in T2DM patients than in NGT and IGT patients, so that at 3 yr glycosylated hemoglobin was no longer different in NGT and T2DM subjects. Clinical and metabolic improvements were proportional to the amount of weight loss. LAGB induced a greater reduction of visceral fat than sc fat. At 1-yr evaluation, weight loss and metabolic improvements were greater in LAGB-treated than diet-treated patients. We conclude that LAGB is an effective treatment of grade 3 obesity in inducing long-lasting reduction of body weight and arterial blood pressure, modifying body fat distribution, and improving glucose and lipid metabolism, especially in T2DM.
Pontiroli
Antonio E
AE
Università degli Studi di Milano, Cattedra di Medicina Interna, Italy.
Pizzocri
Pierluigi
P
Librenti
Maria Cristina
MC
Vedani
Paola
P
Marchi
Monica
M
Cucchi
Emanuele
E
Orena
Corrado
C
Paganelli
Michele
M
Giacomelli
Maurizio
M
Ferla
Gianfranco
G
Folli
Franco
F
D000328:Adult; D001824:Body Constitution; D003920:Diabetes Mellitus / Q000378:metabolism / Q000601:surgery; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D005260:Female; D015391:Gastroplasty / Q000379:methods*; D005951:Glucose Tolerance Test; D006801:Humans; D010535:Laparoscopy; D008297:Male; D009765:Obesity; D009767:Obesity, Morbid / Q000378:metabolism* / Q000601:surgery*; D011183:Postoperative Complications / Q000378:metabolism*; D016896:Treatment Outcome; D015431:Weight Loss